These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1333 related articles for article (PubMed ID: 33115920)

  • 1. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
    Wajnberg A; Amanat F; Firpo A; Altman DR; Bailey MJ; Mansour M; McMahon M; Meade P; Mendu DR; Muellers K; Stadlbauer D; Stone K; Strohmeier S; Simon V; Aberg J; Reich DL; Krammer F; Cordon-Cardo C
    Science; 2020 Dec; 370(6521):1227-1230. PubMed ID: 33115920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
    Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
    J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
    Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
    Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
    Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.
    Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L
    PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
    Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
    Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
    Glöckner S; Hornung F; Baier M; Weis S; Pletz MW; Deinhardt-Emmer S; Löffler B; The CoNAN Study Group
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients.
    Teresa Valenzuela M; Urquidi C; Rodriguez N; Castillo L; Fernández J; Ramírez E
    J Med Virol; 2021 Jul; 93(7):4334-4341. PubMed ID: 33713457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aptamer BC 007's Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies.
    Haberland A; Krylova O; Nikolenko H; Göttel P; Dallmann A; Müller J; Weisshoff H
    Viruses; 2021 May; 13(5):. PubMed ID: 34069827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent and Persistent Antibody Response in COVID-19 Recovered Patients.
    Tian X; Liu L; Jiang W; Zhang H; Liu W; Li J
    Front Immunol; 2021; 12():659041. PubMed ID: 34122416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients.
    Patil HP; Rane PS; Shrivastava S; Palkar S; Lalwani S; Mishra AC; Arankalle VA
    Viral Immunol; 2021 Apr; 34(3):201-209. PubMed ID: 33656935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity.
    Phelan T; Dunne J; Conlon N; Cheallaigh CN; Abbott WM; Faba-Rodriguez R; Amanat F; Krammer F; Little MA; Hughes G; Bergin C; Kerr C; Sundaresan S; Long A; McCormack W; Brady G
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities.
    Noval MG; Kaczmarek ME; Koide A; Rodriguez-Rodriguez BA; Louie P; Tada T; Hattori T; Panchenko T; Romero LA; Teng KW; Bazley A; de Vries M; Samanovic MI; Weiser JN; Aifantis I; Cangiarella J; Mulligan MJ; Desvignes L; Dittmann M; Landau NR; Aguero-Rosenfeld M; Koide S; Stapleford KA
    Sci Rep; 2021 Mar; 11(1):5538. PubMed ID: 33692390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma.
    Tso FY; Lidenge SJ; Poppe LK; Peña PB; Privatt SR; Bennett SJ; Ngowi JR; Mwaiselage J; Belshan M; Siedlik JA; Raine MA; Ochoa JB; Garcia-Diaz J; Nossaman B; Buckner L; Roberts WM; Dean MJ; Ochoa AC; West JT; Wood C
    PLoS One; 2021; 16(3):e0247640. PubMed ID: 33661923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
    Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
    J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
    Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
    J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
    Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
    J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection.
    Jiang XL; Wang GL; Zhao XN; Yan FH; Yao L; Kou ZQ; Ji SX; Zhang XL; Li CB; Duan LJ; Li Y; Zhang YW; Duan Q; Wang TC; Li ET; Wei X; Wang QY; Wang XF; Sun WY; Gao YW; Kang DM; Zhang JY; Ma MJ
    Nat Commun; 2021 Feb; 12(1):897. PubMed ID: 33563974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity.
    Trinité B; Tarrés-Freixas F; Rodon J; Pradenas E; Urrea V; Marfil S; Rodríguez de la Concepción ML; Ávila-Nieto C; Aguilar-Gurrieri C; Barajas A; Ortiz R; Paredes R; Mateu L; Valencia A; Guallar V; Ruiz L; Grau E; Massanella M; Puig J; Chamorro A; Izquierdo-Useros N; Segalés J; Clotet B; Carrillo J; Vergara-Alert J; Blanco J
    Sci Rep; 2021 Jan; 11(1):2608. PubMed ID: 33510275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.